Introduction
JIA is the most frequent form of persistent arthritis in children that begins at or before 16 years old. While outcome of pregnant women with RA is well-known, at best of our knowledge there are a few scientific works about pregnancy in JIA patients [1, 2] .
Objectives
Our aim is to describe pregnancy outcomes in a case series of six women affected by JIA.
Methods
We report on six cases of women affected by JIA with a median age of 32,8; median age at onset of 6,1; median age at first delivery of 25,7. (table 1)
Results
In all cases, pregnancy was associated with remission of disease activity, however a post partum flare appeared after 4 pregnancies ( pt 1-4-5-6) and in the first year postpartum. The seven babies were in good condition, without Pediatrics, Istituto G. Gaslini, Genova, Italy apparent malformation or symptoms of neonatal illness. Only 1 woman was treated during her pregnancy: the number 5 patient received oral cyclosporine for the first 5 months of pregnancy and oral low-dose corticosteroids for all pregnancy; she had an active disease before pregnancy and she had an important flare a few months after delivery.
As reported for pregnant patients affected by RA (Dolhain RJEM 2010), in our cases pregnancy was associated with a remission of disease in 6/6 patients and flare in post-partum period in 4/6 patients, probably depending on increased levels of serum alfa 2 glycoprotein and elevated levels of sex hormones that influence a shift in cytokine production from a Th1 to a Th2 profile. In fact, oestrogens inhibit T-cell function, progesterone stimulates Th2 effects and cortisol has a general immunosuppressive effect.
The number 5 patient was treated with cyclosporine and steroids. No congenital anomalies or increase of death rate were observed in infants exposed to cyclosporine antenatally. Besides low-dose steroids therapy (5-15 mg prednisone daily) does not increase low-birth-weight or small for gestation age infants.
Conclusion
In conclusion, in JIA patients, a stable disease or remission should be reached before pregnancy and should be used safe immunosuppressive drugs to avoid a flare during pregnancy and in post-partum period.
